ADRC THERAPY

Adipose-Derived Regenerative Cells (ADRCs)

Did you know?

Repair and regeneration of adult human organs and tissues after injury or disease requires the presence of adult regenerative cells in these tissues. Adult regenerative cells from a variety of tissues, including bone marrow, peripheral blood, and fat (adipose tissue), have been investigated for tissue repair and regeneration in many disease and injury states. Such cells derived from adipose (fat) tissue are referred to as Adipose-Derived Regenerative Cells (ADRCs). Cytori is developing ADRC-based technology, for the regenerative treatment of chronic heart failure.

ADRCs are a mixed population of cells including adult stem cells, endothelial progenitor cells, leukocytes, endothelial cells, and vascular smooth muscle cells. ADRCs are thought to promote healing of scarred or injured tissue. While the exact mechanisms continue to be investigated, there is scientific evidence that ADRCs counteract inflammation, stimulate new blood vessel formation, prevent cell death, and secrete substances that encourage repair and regeneration.

ADRCs are a unique approach in the field of regenerative medicine with several key advantages over regenerative cells from other sources such as bone marrow and embryonic stem cells.

The ADRCs used in the ATHENA clinical trial, Cytori’s Cell Therapy, are extracted from a patient’s own adipose tissue using a proprietary and patented method developed by Cytori Therapeutics, based in San Diego, CA, USA. The Celution® System automates and standardizes the process of preparing ADRCs from adipose tissue and patients receive their own regenerative cells on the same day as liposuction.